Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Novo Nordisk received positive regulatory recommendations in Europe for Frehemgo (hemophilia A treatment) and Sogroya (growth hormone therapy for multiple indications), potentially diversifying revenue beyond its pressured GLP-1 portfolio. However, the company faces intensifying competition from Eli Lilly's blockbuster GLP-1 drugs and smaller biotechs, with Novo's stock underperforming the industry year-to-date.
Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales and continues driving growth. The company's oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs, while newer therapies grew 121% in Q2, diversifying revenue beyond GLP-1. However, the stock trades at a premium 26.3x forward earnings amid intensifying competition from Novo Nordisk and smaller biotechs in the oral GLP-1 market. Analysts recommend existing investors hold while new investors consider accumulating on market corrections.
Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.